奥希替尼联合赛沃替尼克服EGFR突变伴MET扩增非小细胞肺癌获得性MET介导耐药:TATTON研究
TATTON Ib期研究评估赛沃替尼(600 mg或300 mg每日一次)联合奥希替尼(80 mg每日一次)治疗既往EGFR-TKI进展的MET扩增、EGFR突变晚期非小细胞肺癌患者(B部分138例,D部分42例)。安全性可接受,B部分客观缓解率33%至67%,D部分62%;中位无进展生存期分别为5.5至11.1个月和9.0个月。MET拷贝数≥10时抗肿瘤活性可能增加,治疗中ctDNA EGFR突变清除预测更长的无进展生存期。
要点
- 赛沃替尼联合奥希替尼在MET扩增、EGFR突变晚期NSCLC中安全性可接受
- B部分客观缓解率33%至67%,D部分62%,中位PFS分别为5.5至11.1个月和9.0个月
- MET拷贝数≥10时抗肿瘤活性可能增加,治疗中ctDNA EGFR突变清除预测更长PFS
核心结论
- 赛沃替尼联合奥希替尼是MET扩增/过表达、EGFR突变晚期NSCLC既往EGFR-TKI进展后患者的有前景疗法。
- 该联合方案的获得性耐药机制包括MET、EGFR和KRAS改变。
- 治疗中ctDNA动态可预测临床结局,并可能为早期决策提供机会。
研究设计与样本
- Ib期TATTON研究(NCT02143466)最终分析,B部分138例、D部分42例。
- 患者为MET扩增、EGFR突变晚期NSCLC且既往EGFR-TKI治疗后进展。
- 口服赛沃替尼600 mg或300 mg每日一次联合奥希替尼80 mg每日一次。
主要发现
- 安全性特征可接受。
- B部分客观缓解率为33%至67%,D部分为62%。
- B部分中位无进展生存期为5.5至11.1个月,D部分为9.0个月。
- MET拷贝数≥10时抗肿瘤活性可能增加。
- 基线ctDNA可检测的患者中,治疗中EGFR突变循环肿瘤DNA清除预测更长的无进展生存期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, n = 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + osimertinib 80 mg q.d. in patients with MET-amplified, EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) and progression on prior EGFR-TKI. An acceptable safety profile was observed. In Parts B and D, respectively, objective response rates were 33% to 67% and 62%, and median progression-free survival (PFS) was 5.5 to 11.1 months and 9.0 months. Increased antitumor activity may occur with MET copy number ≥10. EGFRm circulating tumor DNA clearance on treatment predicted longer PFS in patients with detectable baseline ctDNA, while acquired resistance mechanisms to osimertinib + savolitinib were mediated by MET, EGFR, or KRAS alterations. SIGNIFICANCE: The savolitinib + osimertinib combination represents a promising therapy in patients with MET-amplified/overexpressed, EGFRm advanced NSCLC with disease progression on a prior EGFR-TKI. Acquired resistance mechanisms to this combination include those via MET, EGFR, and KRAS. On-treatment ctDNA dynamics can predict clinical outcomes and may provide an opportunity to inform earlier decision-making. This article is highlighted in the In This Issue feature, p. 1.
引用
- Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023. PMID: 36264123. doi:10.1158/2159-8290.CD-22-0586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。